A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507189-17-00

Acronym

17000139BLC2002

Enrollment

Registered

2024-05-03

Start date

2022-01-09

Completion date

Unknown

Last updated

2025-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-Invasive Urothelial Carcinoma of the Bladder

Brief summary

pCR rate at radical cystectomy (RC)

Detailed description

• Frequency and grade of AEs • Laboratory abnormalities • Recurrence-free survival (RFS)

Interventions

DRUGJNJ-63723283

DRUGJNJ-17000139

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
pCR rate at radical cystectomy (RC)	—

Secondary

Measure	Time frame
• Frequency and grade of AEs • Laboratory abnormalities • Recurrence-free survival (RFS)	—

Countries

Belgium, France, Germany, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026